NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of XBiotech, Inc. (NASDAQ: XBIT) concerning possible violations of federal securities laws. On April 20, 2017, XBiotech announced that the European Medicines Agency had rendered a negative trend vote after meeting with the Company to discuss its marketing authorization application (“MAA”) for XBiotech’s candidate antibody for the treatment of colorectal cancer. Then on May 18, 2017, XBiotech announced it had received a negative opinion for its MAA. Then on June 9, 2017, XBiotech announced it had discontinued a Phase 3 study for the treatment after the findings “were not sufficient to meet efficacy or the threshold for continuation.”
If you suffered a loss in XBiotech and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/XBIT-Info-Request-Form-218.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
